American International Group Inc. Has $14.29 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

American International Group Inc. trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 1.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 62,192 shares of the biotechnology company’s stock after selling 1,189 shares during the quarter. American International Group Inc. owned 0.14% of United Therapeutics worth $14,287,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of UTHR. UniSuper Management Pty Ltd lifted its position in United Therapeutics by 133.3% in the first quarter. UniSuper Management Pty Ltd now owns 700 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 400 shares during the period. Seven Eight Capital LP bought a new position in shares of United Therapeutics during the first quarter valued at $1,078,000. Covestor Ltd lifted its holdings in shares of United Therapeutics by 83.1% during the first quarter. Covestor Ltd now owns 509 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 231 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of United Therapeutics by 255.7% during the first quarter. Acadian Asset Management LLC now owns 111,956 shares of the biotechnology company’s stock valued at $25,707,000 after acquiring an additional 80,478 shares during the period. Finally, Intech Investment Management LLC lifted its holdings in shares of United Therapeutics by 1,973.9% during the first quarter. Intech Investment Management LLC now owns 19,412 shares of the biotechnology company’s stock valued at $4,459,000 after acquiring an additional 18,476 shares during the period. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Nilda Mesa sold 266 shares of United Therapeutics stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total value of $84,742.28. Following the completion of the sale, the director now directly owns 5,107 shares in the company, valued at $1,626,988.06. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $331.79, for a total transaction of $1,194,444.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $43,132.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Nilda Mesa sold 266 shares of the business’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total value of $84,742.28. Following the transaction, the director now owns 5,107 shares of the company’s stock, valued at $1,626,988.06. The disclosure for this sale can be found here. Insiders sold a total of 100,884 shares of company stock worth $29,267,123 over the last three months. 12.50% of the stock is currently owned by company insiders.

United Therapeutics Trading Up 2.6 %

UTHR stock traded up $8.51 during midday trading on Thursday, reaching $340.10. The stock had a trading volume of 224,568 shares, compared to its average volume of 491,327. The business has a fifty day simple moving average of $300.45 and a two-hundred day simple moving average of $255.94. The company has a quick ratio of 3.64, a current ratio of 3.77 and a debt-to-equity ratio of 0.04. The firm has a market cap of $15.09 billion, a price-to-earnings ratio of 15.68, a PEG ratio of 1.47 and a beta of 0.55. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $343.98.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. The firm had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company’s revenue was up 33.7% on a year-over-year basis. During the same period last year, the company earned $4.86 earnings per share. As a group, research analysts expect that United Therapeutics Co. will post 24.87 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Oppenheimer lifted their price objective on United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, May 2nd. Morgan Stanley cut United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $310.00 to $321.00 in a report on Thursday, July 11th. HC Wainwright lifted their price objective on United Therapeutics from $300.00 to $400.00 and gave the company a “buy” rating in a report on Thursday. Wells Fargo & Company raised their target price on United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a research note on Wednesday, June 12th. Finally, TD Cowen raised their target price on United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $330.64.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.